A phase Ib/II study of afatinib in combination with nimotuzumab in non–small cell lung cancer patients with acquired resistance to gefitinib or erlotinib

JY Lee, JM Sun, SH Lim, HS Kim, KH Yoo… - Clinical Cancer …, 2016 - AACR
Abstract Purpose: In this phase Ib/II study, we aimed to assess the safety and efficacy of
afatinib plus nimotuzumab (N) in advanced non–small cell lung cancer (NSCLC) patients …
被引用次数：39 相关文章

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.

JY Lee, JM Sun, SH Lim, HS Kim, KH Yoo… - … Cancer Research: an …, 2015 - europepmc.org
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung
Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. - Abstract - Europe PMC Sign …

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

JY Lee, JM Sun, SH Lim, HS Kim, KH Yoo… - Clinical Cancer …, 2015 - hero.epa.gov
PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib
plus nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with …

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

JY Lee, JM Sun, SH Lim, HS Kim… - Clinical Cancer …, 2016 - snucm.elsevierpure.com
Purpose: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus
nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired …

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

JY Lee, JM Sun, SH Lim, HS Kim… - Clinical Cancer …, 2016 - mdanderson.elsevierpure.com
Purpose: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus
nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired …
[PDF] researchgate.net

[PDF][PDF] A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

JY Lee, JM Sun, SH Lim, HS Kim, KH Yoo… - Clin Cancer …, 2016 - researchgate.net
Abstract Purpose: In this phase Ib/II study, we aimed to assess the safety and efficacy of
afatinib plus nimotuzumab (N) in advanced non–small cell lung cancer (NSCLC) patients …

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

JY Lee, JM Sun, SH Lim, HS Kim… - CLINICAL CANCER …, 2016 - scholarworks.bwise.kr
Purpose: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus
nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired …
[PDF] academia.edu

[PDF][PDF] A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

JY Lee, JM Sun, SH Lim, HS Kim, KH Yoo, KS Jung… - Clin Cancer …, 2016 - academia.edu
Abstract Purpose: In this phase Ib/II study, we aimed to assess the safety and efficacy of
afatinib plus nimotuzumab (N) in advanced non–small cell lung cancer (NSCLC) patients …

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

JY Lee, JM Sun, SH Lim, HS Kim… - … : an official journal …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus
nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired …